Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
THE WOODLANDS, Texas, Aug. 30, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D. , Lexicon's president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference in Boston on Wednesday, September 7, 2011 at 2:40 p.m. Eastern Time. Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.
A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com . An archived version of the webcast will be available for 30 days after the event on the company's website.
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com .
Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as w